CRP and metastatic melanoma: We therefore measured body mass, body composition, energy expenditure, energy intake and C-reactive protein (CRP) over several cycles of chemotherapy among patients considered to be at high (non-small-cell lung cancer (NSCLC)) (Buccheri and Ferrigno, 2001) and metastatic melanoma (Smit et al, 1983), and low (metastatic breast) risk of wasting (Jardine et al, 1984).